- Increased incidence of out-of-hospital sudden death (OHSD) has been reported during the coronavirus 2019 (COVID-19) pandemic. New York City (NYC) represents a unique opportunity to examine the epidemiologic association between the two given the variable regional distribution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in its highly diverse neighborhoods.
- Atrial fibrillation (AF) is the most encountered arrhythmia and has been associated with worse in-hospital outcomes.
- The current COVID-19 pandemic has placed extreme stress on the global health care system. Novel approaches to managing COIVD-19 patients are required. Preliminary results from a small trial suggest that a combination of hydroxychloroquine and azithromycin is efficacious for reducing the viral load in patients with COVID-19.1 Although the arrhythmogenic risk of these medications is low, both of these medications alone, and in combination, can prolong the QT interval.1–7 Patients receiving this regimen require, at a minimum, serial electrocardiograms (ECGs), which increases the risk of potential exposures for staff members and requires use of additional personal protective equipment.
- First described in the 1990s, the Brugada syndrome initially characterized unexplained sudden cardiac death in healthy Southeast Asian men.1 Mutations in the cardiac sodium channel were later identified in the SCN5A and SCN10A genes, accounting for nearly 50% of the cases.2,3 Brugada syndrome phenotype is associated with decrease in the sodium current owing to reduction in sodium channels and/or reduction of function of the sodium channels. Although the reduction in the sodium current manifests with characteristic electrocardiographic abnormalities, patients with the Brugada syndrome are often healthy and unaware of their genetic predisposition.